BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20725992)

  • 1. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
    Gaedcke J; Grade M; Jung K; Camps J; Jo P; Emons G; Gehoff A; Sax U; Schirmer M; Becker H; Beissbarth T; Ried T; Ghadimi BM
    Genes Chromosomes Cancer; 2010 Nov; 49(11):1024-34. PubMed ID: 20725992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.
    Saigusa S; Inoue Y; Tanaka K; Toiyama Y; Okugawa Y; Shimura T; Hiro J; Uchida K; Mohri Y; Kusunoki M
    Med Oncol; 2013; 30(3):620. PubMed ID: 23749251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
    Cagnol S; Rivard N
    Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine-Specific Histone Demethylase 1 Promotes Oncogenesis of the Esophageal Squamous Cell Carcinoma by Upregulating DUSP4.
    Han J; Ye S; Chen J; Wang K; Jin J; Zeng Z; Xue S
    Biochemistry (Mosc); 2021 Dec; 86(12):1624-1634. PubMed ID: 34937541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
    Chitale D; Gong Y; Taylor BS; Broderick S; Brennan C; Somwar R; Golas B; Wang L; Motoi N; Szoke J; Reinersman JM; Major J; Sander C; Seshan VE; Zakowski MF; Rusch V; Pao W; Gerald W; Ladanyi M
    Oncogene; 2009 Aug; 28(31):2773-83. PubMed ID: 19525976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
    Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
    Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of
    Varela T; Laizé V; Conceição N; Caldeira P; Marreiros A; Guerreiro H; Cancela ML
    Biomark Med; 2020 Jun; 14(8):639-650. PubMed ID: 32613839
    [No Abstract]   [Full Text] [Related]  

  • 9. The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib.
    Cheng G; Li Y; Liu Z; Song X
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33495832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
    Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
    FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual specificity phosphatase (DUSP)-4 is induced by platelet-derived growth factor -BB in an Erk1/2-, STAT3- and p53-dependent manner.
    Yin R; Eger G; Sarri N; Rorsman C; Heldin CH; Lennartsson J
    Biochem Biophys Res Commun; 2019 Nov; 519(3):469-474. PubMed ID: 31526568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.
    Li KC; Hua KT; Lin YS; Su CY; Ko JY; Hsiao M; Kuo ML; Tan CT
    Mol Cancer; 2014 Jul; 13():172. PubMed ID: 25027955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
    Zhang R; Wang G; Zhang PF; Zhang J; Huang YX; Lu YM; Da W; Sun Q; Zhu JS
    J Cell Mol Med; 2017 Jun; 21(6):1117-1127. PubMed ID: 27957827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
    Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Gupta A; Towers C; Willenbrock F; Brant R; Hodgson DR; Sharpe A; Smith P; Cutts A; Schuh A; Asher R; Myers K; Love S; Collins L; Wise A; Middleton MR; Macaulay VM
    Br J Cancer; 2020 Feb; 122(4):506-516. PubMed ID: 31839677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
    Ichimanda M; Hijiya N; Tsukamoto Y; Uchida T; Nakada C; Akagi T; Etoh T; Iha H; Inomata M; Takekawa M; Moriyama M
    Cancer Sci; 2018 Jan; 109(1):250-258. PubMed ID: 29150975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
    Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
    Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.